H3 Biomedicine, Horizon Discovery Ltd, Eisai deal

H3 Biomedicine will use Horizon's GENESIS recombinant adeno-associated virus (rAAV)-associated genome editing technology and X-Mutant And Normal (X-MAN) human isogenic cell lines to identify and validate genetic targets for personalized cancer treatments. Horizon will receive an undisclosed upfront payment and will be eligible for preclinical and clinical milestones. H3 Biomedicine will conduct early target discovery through preclinical research and its partner Eisai will conduct clinical trials for any resulting targets. H3 Biomedicine will have an exclusive option to acquire all assets and IP related to each resulting target program, excluding Horizon's background IP. Details were not disclosed. ...